A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK-β.
Fan Luo, Ting Yang, Jiaxin Cao, Qun Chen, Zhenhai Lu, Feiteng Lu, Chaozhuo Lin, Zengfei Xia, Yuanzhong Yang, Peng Li, Wenjuan Ma, Min Luo, Rongxin Zhang
Adv Sci (Weinh) 13(12) e14486
摘要
摘要
The ubiquitin-editing enzyme A20 is essential for maintaining inflammatory homeostasis, yet its role in chemoresistance remains unclear. To investigate how A20 regulates oxaliplatin resistance in colorectal cancer (CRC), with a focus on A20-mediated IKK-β monoubiquitylation at K163. A prospective, randomized Phase III study is conducted in patients with locally advanced CRC who received either oxaliplatin+capecitabine neoadjuvant chemoradiotherapy (oxaliplatin-NACRT) or capecitabine-only neoadjuvant chemoradiotherapy (non-oxaliplatin-NACRT). Preoperative biopsy and matched surgical specimens are evaluated by immunohistochemistry to determine A20's association with oxaliplatin response. In oxaliplatin-NACRT group, patients achieving pathological complete response (pCR) displayed lower A20 expression than non-pCR patients, whereas no difference is observed in non-oxaliplatin-NACRT group. Two additional independent cohorts confirmed A20 downregulation in human CRC tissues, and reduced A20 expression correlated with poorer survival and oxaliplatin resistance. Mechanistically, A20 monoubiquitylates IKK-β via its fourth zinc-finger domain, promoting IKK-β degradation and suppressing NF-κB nuclear translocation. A20 knockdown or expression of the IKK-β K163R mutant induced oxaliplatin resistance in mouse xenografts. Clinically, A20 expression are negatively associated with IKK-β and its downstream targets. A20 depletion promotes oxaliplatin resistance in CRC by stabilizing IKK-β. the results uncover an essential role of the A20-IKK-β axis in oxaliplatin resistance of CRC.
KM 提取结果
0 个 Figure · 0 个 KM 面板